Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Stearate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Stearate. Displaying page 1 of 1.
    EudraCT Number: 2007-001391-37 Sponsor Protocol Number: B2C110165 Start Date*: 2007-08-14
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A randomised, single-dose, dose ascending, double-blind, placebo controlled, four-way, incomplete block crossover study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic...
    Medical condition: COPD patients (moderate)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001095-77 Sponsor Protocol Number: AC4105211 Start Date*: 2008-09-19
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability and pharmacokinetics of once-daily inhaled doses of GSK573719 form...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000039-22 Sponsor Protocol Number: CCD-1113-PR-0074 Start Date*: 2012-06-05
    Sponsor Name:CHIESI
    Full Title: AN OPEN LABEL PLACEBO STUDY TO ASSESS THE INHALATION PROFILE OBTAINED BY ACOUSTIC MONITORING IN ASTHMATIC PATIENTS USING THE NEXTHALER DRY POWDER INHALER (DPI) DEVICE.
    Medical condition: Adults asthmatics Patients with varying degrees of disease control.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004807-37 Sponsor Protocol Number: B2C111045 Start Date*: 2008-03-18
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study B2C111045, A Dose-Finding Study of GW642444 versus Placebo in Patients with COPD
    Medical condition: Chronic Pulmonary obstructive Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) EE (Completed) DK (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2008-005779-86 Sponsor Protocol Number: GFT505-208-3 Start Date*: 2008-12-26
    Sponsor Name:GENFIT
    Full Title: A Pilot study to evaluate the Efficacy and Safety of GFT505 (80 mg) orally administered once daily for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-...
    Medical condition: Atherogenic dyslipidaemic patients with abdominal obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058108 Dyslipidaemia LLT
    9.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-006083-33 Sponsor Protocol Number: AC2108378 Start Date*: 2007-02-26
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of twice-daily inhaled dose...
    Medical condition: Study is in COPD patients.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-021986-60 Sponsor Protocol Number: GFT505-210-5 Start Date*: 2010-12-07
    Sponsor Name:GENFIT
    Full Title: A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 12 weeks in patients with Type 2 Diabetes mellitus. A Multicentre, Randomised, Double Blind, Pl...
    Medical condition: Patients with Type 2 Diabetes Mellitus.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2009-011003-23 Sponsor Protocol Number: GFT505-209-4 Start Date*: 2009-05-28
    Sponsor Name:GENFIT
    Full Title: A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 35 days in patients presenting with impaired glucose tolerance and abdominal obesity. A double ...
    Medical condition: patients presenting with impaired glucose tolerance and abdominal obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036481 Pre-diabetes LLT
    9.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-023219-32 Sponsor Protocol Number: GFT505-210-6 Start Date*: Information not available in EudraCT
    Sponsor Name:GENFIT
    Full Title: A Pilot study to evaluate the Efficacy of GFT505 (80mg) orally administered once daily for 8 weeks on insulin sensitivity and hepatic glucose production using a glucose clamp technique and Safety i...
    Medical condition: Patients with insulin resistance and abdominal obesity
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036481 Pre-diabetes LLT
    12.1 10059179 Abdominal obesity LLT
    12.1 10022489 Insulin resistance LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 03:49:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA